CAT-1004, an oral agent targeting NF-κB in development for treatment of Duchenne muscular dystrophy: phase 1/2 study design

Authors
Category Primary study
ConferenceNeuromuscular disorders
Year 2015
This article has no abstract
Epistemonikos ID: da02ee6be14cc4d3b0315953ed0b44fc171a4291
First added on: Feb 07, 2025